Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1630-1636

  Chao, Chun ^a   Tang, Beth ^a   Hurley, Leo ^b   Silverberg, Michael J ^b   Towner, William ^c   Preciado, Melissa ^a   Horberg, Michael ^d  

^a Kaiser Permanente Southern California ^*  (United States)

^b DIVISION OF RESEARCH   (United States)

^c LOS ANGELES MEDICAL CENTER   (United States)

^d Mid Atlantic Permanente Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE;

ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84863813655     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0005     Document Type: Article

References (19)

1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed Aug 31, 2011.
2. Easterbrook PJ, Ives N, Waters A, et al.: The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS 2002; 16(11):1521-1527.
3. Mugavero MJ, Lin HY, Allison JJ, et al.: Racial disparities in HIV virologic failure: Do missed visits matter? J Acquir Immune Defic Syndr 2009;50(1):100-108.
4. Reekie J, Mocroft A, Ledergerber B, et al.: History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med 2010;11(7):469-478.
5. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, and Powderly WG: Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006;7(7):437-441.
6. Benzie AA, Bansi LK, Sabin CA, et al.: Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007;21(11):1423-1430.
7. Paredes R, Mocroft A, Kirk O, et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study. Arch Intern Med 2000;160(8):1123-1132.
8. Phillips AN, Staszewski S, Lampe F, et al.: Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002;186(8):1086-1091.
9. Horberg M, Silverberg M, Hurley L, Delorenze G, and Quesenberry C: Influence of prior antiretroviral experience on adherence and responses to new highly active anti-retroviral therapy regimens. AIDS Patient Care STDS 2008;22(4):301-312.
10. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30.
11. Oette M, Kroidl A, Gobels K, et al.: Predictors of short-term success of antiretroviral therapy in HIV infection. J Anti-microb Chemother 2006;58(1):147-153.
12. Murri R, Lepri AC, Cicconi P, et al.: Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: Evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr 2006; 41(1):23-30.
13. Raffanti SP, Fusco JS, Sherrill BH, et al.: Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004;37(1):1147-1154.
14. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353(9156):863- 868.
15. Moore RD, Keruly JC, Gebo KA, and Lucas GM: An improvement in virologic response to highly active anti-retroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005;39(2):195-198.
16. Deeks SG, Gange SJ, Kitahata MM, et al.: Trends in multi-drug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009;49(10):1582-1590.
17. Moore RD, Stanton D, Gopalan R, and Chaisson RE: Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330(11):763-768.
18. Lillie-Blanton M, Stone VE, Snow Jones A, et al.: Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health 2010;100(8):1493-1499.
19. Silverberg MJ, Leyden W, Quesenberry CP Jr, and Horberg MA: Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med 2009;24(9):1065-1072.